Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AP-472 by Appello Pharmaceuticals for Parkinson's Disease: Likelihood of Approval
AP-472 is under clinical development by Appello Pharmaceuticals and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase...